/MBOT
MBOT Stock - Microbot Medical Inc.
Healthcare|Medical - Instruments & SuppliesNASDAQ
$2.10-1.17%
$0.03 (-1.17%) • Jan 13
64
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.21
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.71
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+161.3%upside
Target: $5.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for MBOT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.08 – $2.13
TARGET (TP)$5.50
STOP LOSS$1.94
RISK/REWARD1:20.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.23
52W High$4.67
52W Low$1.25
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-91,000 | $-106,000 | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-11,625,000 | $-9,855,000 | $-13,281,000 | $-11,357,000 | $-9,089,000 |
| Net Income | $-11,443,000 | $-10,740,000 | $-13,168,000 | $-11,313,000 | $-9,169,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.73 | $-1.05 | $-1.81 | $-1.59 | $-1.29 |
Company Overview
Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company, through its ViRob, TipCAT, CardioSert, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; a disposable robot for various endovascular interventional procedures; and a multi generation pipeline portfolio. It has 42 issued/allowed patents and 23 patent applications pending worldwide. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$6
Average Target
↑ 161.3% Upside
Now
$6
Low
$6
Average
$6
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 3rd 2025 | Roth Capital | Initiation | Buy | $5.5 |
Earnings History & Surprises
MBOTBeat Rate
26%
Last 19 quarters
Avg Surprise
-0.8%
EPS vs Estimate
Beats / Misses
5/9
5 met exactly
Latest EPS
$-0.07
Q4 2025
EPS Surprise History
Q1 24
-4.0%
$-0.26vs$-0.25
Q2 24
0.0%
$-0.17vs$-0.17
Q3 24
0.0%
$-0.17vs$-0.17
Q4 24
-17.6%
$-0.20vs$-0.17
Q1 25
-11.1%
$-0.20vs$-0.18
Q2 25
+38.5%
$-0.08vs$-0.13
Q3 25
-25.0%
$-0.10vs$-0.08
Q4 25
-16.7%
$-0.07vs$-0.06
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 24, 2026 | $-0.07 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.06 | $-0.07 | -16.7% | ✗ MISS |
Q3 2025 | Aug 12, 2025 | $-0.08 | $-0.10 | -25.0% | ✗ MISS |
Q2 2025 | May 14, 2025 | $-0.13 | $-0.08 | +38.5% | ✓ BEAT |
Q1 2025 | Mar 25, 2025 | $-0.18 | $-0.20 | -11.1% | ✗ MISS |
Q4 2024 | Nov 13, 2024 | $-0.17 | $-0.20 | -17.6% | ✗ MISS |
Q3 2024 | Aug 14, 2024 | $-0.17 | $-0.17 | 0.0% | = MET |
Q2 2024 | May 15, 2024 | $-0.17 | $-0.17 | 0.0% | = MET |
Q1 2024 | Mar 27, 2024 | $-0.25 | $-0.26 | -4.0% | ✗ MISS |
Q4 2023 | Nov 14, 2023 | $-0.25 | $-0.21 | +16.0% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-0.31 | $-0.25 | +19.4% | ✓ BEAT |
Q1 2023 | Mar 31, 2023 | $-0.45 | $-0.38 | +15.6% | ✓ BEAT |
Q1 2023 | Mar 29, 2023 | $-0.47 | $-0.54 | -14.9% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-0.51 | $-0.49 | +3.9% | ✓ BEAT |
Q3 2022 | Aug 15, 2022 | $-0.45 | $-0.49 | -8.9% | ✗ MISS |
Q2 2022 | May 16, 2022 | $-0.42 | $-0.45 | -7.1% | ✗ MISS |
Q1 2022 | Mar 31, 2022 | $-0.54 | $-0.54 | 0.0% | = MET |
Q4 2021 | Nov 15, 2021 | $-0.36 | $-0.36 | 0.0% | = MET |
Q3 2021 | Aug 16, 2021 | $-0.35 | $-0.35 | 0.0% | = MET |
Q2 2021 | May 17, 2021 | $-0.33 | $-0.34 | -3.0% | ✗ MISS |
Latest News
Microbot Medical Says It Enters 2026 With Market Momentum Following FDA 510(k) Clearance Of LIBERTY, Single‑Use Endovascular Robotic System
📈 PositiveBenzinga•Jan 12, 2026, 01:35 PM
Roth Capital Initiates Coverage On Microbot Medical with Buy Rating, Announces Price Target of $5.5
📈 PositiveBenzinga•Dec 3, 2025, 05:58 PM
HC Wainwright & Co. Reiterates Buy on Microbot Medical, Maintains $12 Price Target
📈 PositiveBenzinga•Nov 28, 2025, 12:08 PM
Microbot Medical Says Emory University Hospital Adopts LIBERTY For Patient Care; Microbot Collaborates With Emory To Establish Endovascular Robotics Program In Interventional Radiology
📈 PositiveBenzinga•Nov 26, 2025, 01:35 PM
Microbot Medical Announces Commercial Availability Of LIBERTY Robotic System In U.S.
📈 PositiveBenzinga•Nov 5, 2025, 01:34 PM
Microbot Medical Announces It Will Exhibit Its Liberty Endovascular Robotic System At Symposium On Clinical Interventional Oncology In Miami, Fl, October 17-19, 2025, Marking First Commercial Exhibition Of The System Following Its FDA 510(K) Clearance In September 2025
📈 PositiveBenzinga•Oct 16, 2025, 12:38 PM
HC Wainwright & Co. Reiterates Buy on Microbot Medical, Maintains $12 Price Target
📈 PositiveBenzinga•Oct 15, 2025, 10:46 AM
Microbot Medical Partners With U.S. Based 3PL Company To Support Commercialization Of FDA-Cleared LIBERTY System
📈 PositiveBenzinga•Oct 14, 2025, 12:32 PM
Microbot Medical Announces That The Japanese Patent Office Has Granted The Company Its First Patent In Japan, Covering The Core LIBERTY System Technology
📈 PositiveBenzinga•Oct 1, 2025, 01:14 PM
Microbot Medical Enters Into Agreements To Purchase Up To 13,989,115 Shares Of Common Stock In Two Tranches For Up To $92.2M In Gross Proceeds
📈 PositiveBenzinga•Sep 15, 2025, 12:13 PM
HC Wainwright & Co. Maintains Buy on Microbot Medical, Raises Price Target to $12
📈 PositiveBenzinga•Sep 11, 2025, 11:24 AM
Microbot Medical shares are trading higher after the company announced that the FDA granted the company 510(k) clearance for the LIBERTY System.
📈 PositiveBenzinga•Sep 8, 2025, 04:21 PM
Microbot Medical Receives FDA 510(k) Clearance For LIBERTY Robotic System, Targets Q4 2025 Commercial Launch
📈 PositiveBenzinga•Sep 8, 2025, 12:28 PM
Microbot Medical Option Alert: Jan 16 $2.5 Calls at the Ask: 20000 @ $2.05 vs 39143 OI; Ref=$4.525
📈 PositiveBenzinga•Aug 25, 2025, 02:49 PM
MicroMedical shares are trading higher. The stock may be moving on continued strength after the company announced that the U.S. Patent and Trademark Office has granted it a patent covering robotic surgical systems on Wednesday.
📈 PositiveBenzinga•Aug 21, 2025, 06:04 PM
US Patent And Trademark Office Grants Microbot Medical Patent Covering Modular Robotic Surgical System Includes Base And Plurality Of Tool-Receiver Units Arranged As Separate Units And Independently And Interchangeably Attachable To Base
📈 PositiveBenzinga•Aug 20, 2025, 12:40 PM
Frequently Asked Questions about MBOT
What is MBOT's current stock price?
Microbot Medical Inc. (MBOT) is currently trading at $2.10 per share. The stock has moved -1.17% today.
What is the analyst price target for MBOT?
The average analyst price target for MBOT is $5.50, based on 1 analyst.
What sector is Microbot Medical Inc. in?
Microbot Medical Inc. operates in the Healthcare sector, specifically within the Medical - Instruments & Supplies industry. The company is traded on the NASDAQ exchange.
What is MBOT's market cap?
Microbot Medical Inc. has a market capitalization of $0.10 billion, making it a small-cap company.
Does MBOT pay dividends?
No, Microbot Medical Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCLNN
Clene Inc.
$4.86
Mkt Cap: $0.0B
CNTX
Context Therapeutics Inc.
$1.50
Mkt Cap: $0.1B
CRDL
Cardiol Therapeutics Inc.
$0.96
Mkt Cap: $0.1B
DCGO
DocGo Inc.
$0.89
Mkt Cap: $0.1B
NSPR
InspireMD, Inc.
$1.57
Mkt Cap: $0.1B
ORMP
Oramed Pharmaceuticals Inc.
$3.49
Mkt Cap: $0.1B
OVID
Ovid Therapeutics Inc.
$1.60
Mkt Cap: $0.1B
RCEL
AVITA Medical, Inc.
$3.32
Mkt Cap: $0.1B
VANI
Vivani Medical, Inc.
$1.31
Mkt Cap: $0.1B
ZTEK
Zentek Ltd.
$1.03
Mkt Cap: $0.1B
Explore stocks similar to MBOT for comparison